Oral Ibrexafungerp (SCY-078) in Refractory Fungal Diseases
^{Interim Analysis by Pathogen of a Phase 3 Open-label Study (FURI)}

Oliver A. Cornely MD, FECMM, FIDSA, FAAM, FACP
Consultant, Infectious Diseases
Director, European Mycology Excellence Center
University Hospital of Cologne
ECCMID 2019
April 2019

Successful Treatment of Two Patients with Candida auris Candidemia with the Investigational Agent, Oral Ibrexafungerp (formerly SCY-078), from the CARES Study

Favourable Clinical Outcome of Two Patients with Candida spp. Spondylodiscitis treated with Oral Ibrexafungerp (formerly SCY-078) from the FURI Study

Use of Ibrexafungerp (formerly SCY-078) to Treat Severe Azole Refractory Esophageal Candidiasis. A Case Report from the Furi Study

Penetration of Ibrexafungerp (formerly SCY-078) versus Micafungin at the Site of Infection in an Intra-abdominal Candidiasis Mouse Model

Efficacy of Ibrexafungerp (formerly SCY-078) Against Pneumocystis Pneumonia in a Murine Therapeutic Model.

Ibrexafungerp: Activity against Pneumocystis

Ibrexafungerp (formerly SCY-078) Displays Potent In Vitro Activity Against C. glabrata Isolates with Mutations in fks Genes

Stephen Barat, Katyna Borroto-Esoda, David Angulo
ESCMID ASM 2018
September 2018

SCY-078: A first-in-class, orally-bioavailable, glucan synthase inhibitor has broad spectrum activity against Candida, Aspergillus and Pneumocystis spp.

Stephen Barat, Katyna Borroto-Esoda, David Angulo
ISHAM 2018
June 2018

In vitro Activity of SCY-078 in Combination with Isavuconazole or Amphotericin B against Medically Important Moulds